Stay updated on Pembrolizumab for EGFR+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for EGFR+ NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-19T14:52:09.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-12T14:55:32.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    30 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden error, replacing the previous content and removing several study documents and related links from the page.
    Difference
    19%
    Check dated 2026-09-21T22:09:29.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    Revision updated from v3.6.5 to v3.6.6 on the page, indicating a minor backend/template update. No study content or data appears to be changed.
    Difference
    0.1%
    Check dated 2026-08-31T18:10:54.000Z thumbnail image
  6. Check
    72 days ago
    Change Detected
    Summary
    A software revision label on the page was updated from v3.6.4 to v3.6.5. This reflects a version bump and does not modify the study information or functionality visible to users.
    Difference
    0.1%
    Check dated 2026-08-10T13:28:40.000Z thumbnail image
  7. Check
    86 days ago
    Change Detected
    Summary
    A new revision tag `Revision: v3.6.4` was added, replacing the previous `Revision: v3.6.3`. This indicates an update to the page's build or versioning metadata without modifying the study details presented.
    Difference
    0.1%
    Check dated 2026-07-27T05:52:21.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for EGFR+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.